Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: per strandberg who wrote (3655)	1/25/1998 1:11:00 AM
From: Larry Liebman	Read Replies (1) \| Respond to of 6136

I was looking at relative valuation vis-a-vis Amgen. AMGN has product sales of $2 billion+ with a market cap of roughly $13 billion. The company is trading at 6.5x sales, with prospects for increasing sales of their 2 flagship products being limited. It is also trading near its 52 week low. AGPH, with European sales to commence, is looking at sales of $400 million+, with its capitalization being approximately $1 billion. It is trading at 2.5x sales. I suspect AMGN's valuation is high, AGPH's low.